AUS
NZ
UK
CA
USA
IND
Investors in ASX healthcare stocks are witnessing a remarkable surge in the share price of Volpara Health Technologies Ltd (ASX:VHT), which has climbed by 13% to 72.5 cents in afternoon trade on Tuesday. The health technology company's shares are attracting strong interest, buoyed by the positive response to its latest quarterly update.
For the three months ending September 30, Volpara reported record cash receipts of NZ$11.5 million, signaling a robust 32% increase over the prior corresponding period. This stellar financial performance has resonated positively with investors focused on ASX healthcare stocks. The company closed the quarter with contracted annual recurring revenue (CARR) of approximately US$28.4 million (~NZ$46.3 million), a notable uptick of over US$1.2 million since the end of June. Volpara's annual recurring revenue (ARR) also exhibited growth, reaching approximately US$22.5 million (~NZ$36.6 million), up from US$21.5 million in the preceding quarter.
The significant surge in the ASX VHT share price can be attributed to its positive net operating cash flow of NZ$1.2 million for the quarter. This achievement is particularly noteworthy as it marks the fourth consecutive quarter of positive net operating cash flow. Impressively, Volpara has surpassed its cash flow target 18 months ahead of plan, reinforcing its financial strength. The company's management has decided that, given this achievement, it is no longer obliged to provide Appendix 4C quarterly reporting updates. However, a commitment to offering regular operational and financial updates to shareholders remains intact, with periodic business updates planned.
Teri Thomas, Volpara's CEO and Managing Director, expressed her delight with the quarter's performance, highlighting its significance as a milestone quarter for the company. She emphasized the positive impact of Volpara's software on families and its record number of contract renewals. Thomas also drew attention to the forthcoming launch of a new product named Quiver, scheduled for release next year. As part of Volpara's growth strategy, Quiver, leveraging the Analytics platform, aims to provide administrative simplification for mammography centers, allowing them to allocate more time to patient care.
As investors assess Volpara within the realm of ASX healthcare stocks, the company's strong quarterly results and commitment to innovation position it favorably in the healthcare sector. The positive financial indicators and growth endeavors contribute to growing confidence in Volpara's market position and future prospects.
